Trump unveils 100-percent tariff on drugs to push for pharmaceutical deals

President Trump signed an executive order enabling tariffs of up to 100% on some patented drugs if companies do not reach pricing deals; companies with 'most favoured nation' pricing and active US facilities receive a 0% tariff, while firms building US projects face 20% now rising to 100% in four years. The administration said larger firms get 120 days and others 180 days to negotiate; it has reached 17 pricing deals (13 signed). Targeted country rates: EU, Japan, Korea and Switzerland 15%; UK 10% (to be reduced to zero under future agreements). Industry groups warn the levies could raise drug costs and jeopardize US biopharma investment.

Analysis

This policy acts as a forcing function for pharmaceutical supply-chain reconfiguration: expect accelerated capital allocation into US-based contract manufacturing, biologics fill/finish, and specialized logistics over a 12–36 month window. Those buildouts are multi-year capex programs that favor large, incumbent CMOs and equipment vendors with spare capacity and validated quality systems; revenue and margin tailwinds will lag announcements by quarters but compound materially once multi-product transfer programs scale.

Smaller generics and import-reliant formulators are the most exposed — their unit economics and working-capital profiles make them vulnerable to margin compression and funding stress if access to lower-cost foreign API and finished-dose supply is curtailed. Simultaneously, countries and companies that secure bilateral carve-outs or trade frameworks will retain pricing advantages, creating a two-tier competitive landscape that widens dispersion across mid-cap pharma equities and credit.

Near-term event risks center on deal-by-deal negotiations and legal/political pushback; outcomes over the next 3–9 months will drive equity re-ratings, while onshoring outcomes are a 1–3 year structural story. A key reversal vector is rapid bilateral trade agreements or court intervention that limits scope, which would shrink the premium for domestic-capacity beneficiaries and restore competitiveness for import-dependent players.

Watchables that will move prices: announcements of major CMO capacity commitments, financing activity from vulnerable generics (equity raises or covenant waivers), and any formal trade carve-outs. These milestones create discrete entry/exit windows and asymmetric payoff profiles between service providers (beneficiaries) and import-dependent manufacturers (losers).

Key Decisions for Investors

• Long Catalent (CTLT) via 12–18 month call spread (buy near-ATM calls, sell 25–35% OTM) — rationale: capture onshoring capex and outsized CMO volume growth with capped premium; target 2.5:1 upside to max loss if multiple multi-product transfers announced over 12 months.
• Long Thermo Fisher (TMO) outright (12–24 month horizon) — exposure to equipment/reagents/logistics tailwinds; defensive versus policy reversal risk. Take profits on a 20–30% rally; hedge with 10–15% notional put if trade-policy headlines soften.
• Pair trade: Long CTLT / Short Viatris (VTRS) or TEVA (choose single short by valuation/credit health) over 6–18 months — captures dispersion between US CMOs and import-dependent generics. Aim for asymmetric payoff: 3:1 if tariffs or carve-outs materialize; stop-loss if macro/legal reversal occurs.
• Event-driven idea: Monitor and buy volatility ahead of major negotiation deadlines for large-cap issuers (e.g., PFE, BMY, LLY) — purchase near-term straddles or strangles 30–60 days before announced deal windows to monetize deal/no-deal swings. Expect binary returns; size small relative to core positions.